Toll-like receptor 2 in promoting angiogenesis after acute ischemic injury

International Journal of Molecular Medicine

Volumn 31, Issue 3, 2013, Pages 555-560

  Xu, Yifei ^a   Zhou, Ying ^a   Lin, Haiyan ^a   Hu, Haiyang ^a   Wang, Yuxing ^a   Xu, Geng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiogenesis; Interleukin 6; Ischemia; Lymphocyte; Toll like receptor 2; Tumor necrosis factor

Indexed keywords

CD31 ANTIGEN; INTERLEUKIN 6; LIPOPEPTIDE; PAM3CSK4; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL ASSAY; CELL INVASION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GASTROCNEMIUS MUSCLE; HINDLIMB; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGATION; LYMPHOCYTE; MOUSE; MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WILD TYPE; WOUND HEALING;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; CELL MOVEMENT; CELLS, CULTURED; ENZYME ACTIVATION; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; ISCHEMIA; LIPOPEPTIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873126607     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1240     Document Type: Article

References (33)

1. Faxon DP, Fuster V, Libby P, et al: Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 109: 2617-2625, 2004.
2. Dormandy J, Heeck L and Vig S: Acute limb ischemia. Semin Vasc Surg 12: 148-153, 1999.
3. Costantini V and Lenti M: Treatment of acute occlusion of peripheral arteries. Thromb Res 106: V285-V294, 2002.
4. Isner JM: Therapeutic angiogenesis: a new frontier for vascular therapy. Vasc Med 1: 79-87, 1996.
5. Chen YC, Hsiao CC, Chen CJ, et al: Toll-like receptor 2 gene polymorphisms, pulmonary tuberculosis, and natural killer cell counts. BMC Med Genet 11: 17, 2010.
6. Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell 124: 783-801, 2006.
7. Medzhitov R, Preston-Hurlburt P and Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997.
8. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
9. Shigeoka AA, Holscher TD, King AJ, et al: TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J Immunol 178: 6252-6258, 2007.
10. Leemans JC, Stokman G, Claessen N, et al: Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 115: 2894-2903, 2005.
11. Favre J, Musette P, Douin-Echinard V, et al: Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 27: 1064-1071, 2007.
12. Mersmann J, Berkels R, Zacharowski P, et al: Preconditioning by Toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med 38: 903-909, 2010.
13. Hua F, Ma J, Ha T, et al: Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol 199: 75-82, 2008.
14. Ha T, Lu C, Liu L, et al: TLR2 ligands attenuate cardiac dysfunction in polymicrobial sepsis via a phosphoinositide 3-kinase-dependent mechanism. Am J Physiol Heart Circ Physiol 298: H984-H991, 2010.
15. Chang YJ, Wu MS, Lin JT and Chen CC: Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 175: 8242-8252, 2005.
16. Scholz D, Ziegelhoeffer T, Helisch A, et al: Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 34: 775-787, 2002.
17. Martin P, D'Souza D, Martin J, et al: Wound healing in the PU.1 null mouse -tissue repair is not dependent on inflammatory cells. Curr Biol 13: 1122-1128, 2003.
18. Saber T, Veale DJ, Balogh E, et al: Toll-like receptor 2 induced angiogenesis and invasion is mediated through the Tie2 signalling pathway in rheumatoid arthritis. PLoS One 6: e23540, 2011.
19. Muller WA, Ratti CM, McDonnell SL and Cohn ZA: A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med 170: 399-414, 1989.
20. Newman PJ, Berndt MC, Gorski J, et al: PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247: 1219-1222, 1990.
21. Muller WA: Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 24: 327-334, 2003.
22. Balkwill F: Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371, 2009.
23. Balkwill F: TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25: 409-416, 2006.
24. Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183, 2007.
25. Ancrile B, Lim KH and Counter CM: Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719, 2007.
26. Huang SP, Wu MS, Shun CT, et al: Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11: 517-527, 2004.
27. Fan Y, Ye J, Shen F, et al: Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 28: 90-98, 2008.
28. Lin H, Yan J, Wang Z, et al: Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in TLR2-deficient mouse. Hepatology: Aug 1, 2012 (Epub ahead of print). doi: 10.1002/hep.25991.
29. Amura CR, Renner B, Lyubchenko T, Faubel S, Simonian PL and Thurman JM: Complement activation and Toll-like receptor-2 signaling contribute to cytokine production after renal ischemia/reperfusion. Mol Immunol 52: 249-257, 2012.
30. Correa-Costa M, Braga TT, Semedo P, et al: Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PLoS One 6: e29004, 2011.
31. Xie W, Wang Y, Huang Y, Yang H, Wang J and Hu Z: Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 379: 1027-1032, 2009.
32. Shuto T, Ono T, Ohira Y, et al: Curcumin decreases Toll-like receptor-2 gene expression and function in human monocytes and neutrophils. Biochem Biophys Res Commun 398: 647-652, 2010.
33. Jang JH, Yang ES, Min KJ and Kwon TK: Inhibitory effect of butein on tumor necrosis factor-α-induced expression of cell adhesion molecules in human lung epithelial cells via inhibition of reactive oxygen species generation, NF-κB activation and Akt phosphorylation. Int J Mol Med 30: 1357-1364, 2012.